Increased Assay Panel of SNPs

An assay panel with 20,000 non-synonymous single nucleotide polymorphisms (SNPs) is now available for use in human genotyping studies.

The assay panel, from ParAllele Genotyping Services (So. San Francisco, CA, USA), formerly had only 10,000 SNPs. This enlarged coding SNP panel represents genes with SNPs that code for amino acid changes, which are those believed to have the biggest impact on phenotype. The panel was developed by using the company's molecular inversion probes, which result in extremely high levels of multiplexing, essential for genotyping demands. This latest panel also includes some of those selected by ParAllele from > 25,000 previously unvalidated SNPS. The final SNP panel selection for the enlarged panel was achieved by genotyping around 300 individuals from three ethnic populations accounting for > 8 million genotypes.

"This panel enlarged to 20,000 fully validated non-synonymous SNPs not only represents a cost-effective way of achieving whole genome analysis but has the potential of an extremely high payoff, since the SNPs that we have selected for this assay panel represent those most likely to be associated with a functional response,” said Malek Farhem, M.D., Ph.D., co-founder and director of research at ParAllele.

The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome.




Related Links:
ParAllele